Physician profile
Constantine Kashnikow
NPI 1811956881
$4,651.66
in general payments reported to CMS, 2019-2025
30 companies · $329 in 2025
The $329 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $691 · 2021: $817 · 2022: $634 · 2023: $906 · 2024: $553 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,787.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $700.73 | 2019-2025 | Repatha |
| Merck Sharp & Dohme LLC | $654.60 | 2021-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $484.31 | 2019-2025 | |
| Amarin Pharma, INC. | $320.39 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $287.51 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $286.29 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $229.17 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $207.36 | 2020-2023 | Farxiga |
| Boston Scientific Corporation | $184.85 | 2020-2024 | |
| Sanofi-Aventis U.S. LLC | $184.81 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.54 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $170.87 | 2019-2025 | Camzyos, Eliquis |
| Kowa Pharmaceuticals America, INC. | $152.71 | 2019-2021 | |
| Esperion Therapeutics, INC. | $129.64 | 2020-2025 | Nexletol |
| Lundbeck LLC | $101.28 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $68.40 | 2019 | |
| Azurity Pharmaceuticals, INC. | $50.61 | 2023 | Edarbi |
| Baxter Healthcare | $33.51 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Abiomed | $28.42 | 2019 | |
| Althera Pharmaceuticals LLC | $26.54 | 2021-2022 | |
| Abbott Laboratories | $23.61 | 2025 | Aveir |
| Bardy Diagnostics, INC. | $20.43 | 2020 | |
| Infobionic, INC | $18.92 | 2020 | |
| Edwards Lifesciences Corporation | $18.07 | 2025 | Sapien 3 Ultra Resilia |
| Glaxosmithkline, LLC. | $17.06 | 2025 | Shingrix, Arexvy |
| Arbor Pharmaceuticals, INC. | $16.64 | 2019 | |
| Cleerly, INC. | $16.33 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Alnylam Pharmaceuticals INC. | $15.92 | 2024 | Onpattro |
| Irhythm Technologies, INC. | $15.48 | 2022 | |
| Amryt Pharma Holdings LTD | $13.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constantine Kashnikow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.